Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Next revision		Previous revision
ms [2023/07/03 09:34] – created - external edit 127.0.0.1ms [2024/04/06 15:50] (current) – [Multiple Sclerosis] sflitman
Line 5: Line 5:
 <html><!-- <html><!--
 New trials are coming, please watch this space.   New trials are coming, please watch this space.  
 +| Relapsing-Remitting Multiple Sclerosis |  Oral BKT inhibitor  |  III  |  Teriflunomide  |  96 weeks  |  Up to 96 weeks  |
 +
 +
 --></html> --></html>
  
  
 ^  Condition  ^  Type of Drug  ^  Phase  ^  Comparator  ^  Duration  ^  Open Label Extension  ^ ^  Condition  ^  Type of Drug  ^  Phase  ^  Comparator  ^  Duration  ^  Open Label Extension  ^
-| Primary Progressive Multiple Sclerosis |  Higher dose of approved Ocrevus infusion  |  III  |  Regular dose Ocrevus  |  2 years  |  Up to 6 years  | 
-| Relapsing-Remitting Multiple Sclerosis |  Oral BKT inhibitor  |  III  |  Teriflunomide  |  96 weeks  |  Up to 96 weeks  | 
 | Relapsing-Remitting Multiple Sclerosis |  Oral DHODH inhibitor  |  III  |  None  |  72 weeks  |  Up to 8 years  | | Relapsing-Remitting Multiple Sclerosis |  Oral DHODH inhibitor  |  III  |  None  |  72 weeks  |  Up to 8 years  |
 +| Multiple Sclerosis |  Oral Nerve Repair Agent  |  I  |  None  |  48 weeks  |  Anticipated  |
  
  

Trace:

Print/export
QR Code
QR Code ms (generated for current page)